Diligence memo · auto-generated · as of July 2, 2026
Alder Biopharmaceuticals Inc
Alder Biopharmaceuticals Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Alder Biopharmaceuticals Inc operates in Biotechnology, based in BOTHELL.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Alder Biopharmaceuticals Inc has raised $100M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $100M on 2018-01-12.
Most recent recorded round closed around 2018-01-12.
Valuation (modeled)modeled
Provath models Alder Biopharmaceuticals Inc at approximately $4.1B (range $309M–$10.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.00× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 8.5 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 90% of Biotechnology peers (4293 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Genesis Biopharma, Inc, Ideaya Biosciences, Inc., Stoke Therapeutics, Inc., 4D Molecular Therapeutics Inc, Sutro Biopharma Inc.
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.